1. Home
  2. ELA vs CHRS Comparison

ELA vs CHRS Comparison

Compare ELA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Envela Corporation

ELA

Envela Corporation

HOLD

Current Price

$17.50

Market Cap

433.6M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.73

Market Cap

291.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELA
CHRS
Founded
1965
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
433.6M
291.5M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
ELA
CHRS
Price
$17.50
$1.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$16.50
$5.51
AVG Volume (30 Days)
168.1K
1.3M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
115.38
472.00
EPS
0.56
1.43
Revenue
$241,021,362.00
N/A
Revenue This Year
N/A
$73.08
Revenue Next Year
$17.30
$30.94
P/E Ratio
$30.95
$1.20
Revenue Growth
33.62
N/A
52 Week Low
$5.33
$0.72
52 Week High
$18.29
$2.62

Technical Indicators

Market Signals
Indicator
ELA
CHRS
Relative Strength Index (RSI) 70.32 50.70
Support Level $11.05 $1.55
Resistance Level $18.29 $1.78
Average True Range (ATR) 1.14 0.10
MACD 0.25 0.01
Stochastic Oscillator 89.02 57.58

Price Performance

Historical Comparison
ELA
CHRS

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: